Locally Advanced Gastric or Gastroesophageal Junction Cancer
Conditions
Brief summary
This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.
Interventions
DRUGAdebrelimab plus S-1 and oxaliplatin
Adebrelimab plus S-1 and oxaliplatin
DRUGAdebrelimab blank preparation plus S-1 and oxaliplatin.
Adebrelimab blank preparation plus S-1 and oxaliplatin.
Sponsors
Shanghai Shengdi Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with pathologically confirmed gastric cancer or gastroesophageal junction cancer. 2. Age: ≥18 years old, \<75 years old, both male and female are eligible. 3. Before entering the study, the investigator has evaluated and determined that the subject is suitable and plans to undergo neoadjuvant therapy + radical surgery for curative purposes. 4. Gastric cancer or gastroesophageal junction cancer applicable to the 8th edition of the AJCC gastric cancer staging criteria. 5. Fresh specimens (preferred) or formalin-fixed, paraffin-embedded tumor tissue blocks or unstained tumor specimen sections obtained within 6 months before randomization can be provided. 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1. 7. Expected survival ≥ 6 months. 8. Adequate organ and bone marrow function. 9. Female subjects are either infertile or fertile, with a negative serum pregnancy test result within 3 days before the start of study medication and not in the lactation period. Fertile female subjects and male subjects whose partners are fertile must agree to avoid sperm/egg donation from the time of signing the informed consent form until 6 months after the last administration of the investigational drug, and comply with relevant contraceptive requirements. 10. Consent has been obtained from the individual and the informed consent form has been signed, willing and able to comply with planned visits, study treatment, laboratory tests, and other trial procedures.
Exclusion criteria
1. Gastric cancer known to be squamous cell carcinoma, undifferentiated carcinoma or other histological types, or adenocarcinoma mixed with other histological types. 2. Gastric esophageal junction cancer, Siewert type I; or Siewert type II with esophageal invasion length ≥ 4 cm; or other cases not suitable for clinical staging assessment using the 8th edition of the AJCC gastric cancer staging criteria, or not suitable for conventional surgical methods or approaches for gastric cancer. 3. The subject's weight has decreased by more than 20% within 2 months before randomization. 4. Previous anti-tumor treatment for gastric cancer/gastric esophageal junction cancer (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy or tumor embolization). 5. Known allergy to any component of the investigational drug (including adibelimab/placebo, tegafur, and oxaliplatin), or allergy to humanized monoclonal antibody products. 6. Diagnosis of any other malignant tumor within 5 years before entering the study, except for locally treatable and cured skin basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma. 7. History of immunodeficiency (including positive HIV test, other acquired or congenital immunodeficiency diseases) or organ transplantation (including allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, etc.); history of active autoimmune disease, except for immune disorders that do not require systemic treatment (such as vitiligo, psoriasis, etc.) or autoimmune diseases that can be improved through hormone replacement therapy (such as type 1 diabetes or hypothyroidism). 8. Severe, unhealed or open wounds, active ulcers, or untreated fractures. 9. Active severe digestive system diseases. 10. Presence of interstitial pneumonia or interstitial lung disease. 11. Severe cardiovascular or metabolic diseases. 12. Active HBV or HCV infection (HBsAg positive and viral copy number ≥ 2000 IU/mL, HCV antibody positive and HCV RNA above the upper limit of normal at the research center), or co-infection with hepatitis B and hepatitis C. 13. Active tuberculosis infection within 1 year before randomization (including but not limited to pulmonary tuberculosis, intestinal tuberculosis, etc.), or a history of active tuberculosis infection more than 1 year ago but without regular treatment. 14. Severe infection within 4 weeks before randomization. 15. Known history of abuse of psychotropic drugs or drug addiction. 16. Presence of other serious physical or mental diseases or abnormal laboratory tests that may increase the risk of participation in the study, or interfere with the study results, and patients considered unsuitable for participation in the study by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Investigator-assessed EFS | About 8 years | Assessments BY INVESTIGATORS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete response (pCR) rate as assessed by the Pathology Review Committee (PRC) | About 3 years | Complete remission (pCR) rates after surgery |
| Rate of pathologically significant response (MPR) as assessed by the Pathology Review Committee (PRC) | About 3 years | Pathologically significant response (MPR) rate after surgery |
| EFS as assessed by an independent review committee (IRC) | About 8 years | Independent Review Committee (IRC) evaluation |
| DFS, as assessed by investigator /IRC | About 8 years | Investigator /IRC assessment |
| pCR rate by central pathological evaluation | About 3 years | Central pathological evaluation was studied |
| R0 resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups | About 8 years | Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator |
| D2 radical resection rate of neoadjuvant therapy evaluated by investigators in different treatment groups | About 8 years | Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator |
| objective response rate (ORR) of neoadjuvant therapy evaluated by investigators in different treatment groups | About 8 years | Patients who did not undergo surgery for gastric or gastroesophageal junction cancer because of various conditions other than disease progression were evaluated by the investigator |
| The incidence of adverse events (AE) were evaluated according to NCI-CTCAE 6.0 | About 4 years | NCI-CTCAE 6.0 was used for evaluation |
| The severity of serious adverse events (SAE) were evaluated according to NCI-CTCAE 6.0 | About 4 years | NCI-CTCAE 6.0 was used for evaluation |
Countries
China
Contacts
CONTACTBin Bai
Outcome results
None listed